News Release

KIAA0930: A cachexic phenotype inducer in cancer cells

Peer-Reviewed Publication

Impact Journals LLC

Figure 2

image: Figure 2: ShRNAs targeting KIAA0930 decrease KIAA0930 mRNA expression and suppress muscle atrophy in PANC-1 cells in vitro. view more 

Credit: 2023 Yamakawa et al.

“We believe that KIAA0930 would be a novel cachexia therapeutic target.”

BUFFALO, NY- July 26, 2023 – A new research paper was published in Oncotarget's Volume 14 on July 20, 2023, entitled, “The uncharacterized transcript KIAA0930 confers a cachexic phenotype on cancer cells.”

Patients with cancer cachexia have a poor prognosis and impaired quality of life. Numerous studies using preclinical models have shown that inflammatory cytokines play an important role in the development of cancer cachexia; however, no clinical trial targeting cytokines has been successful. Therefore, it is essential to identify molecular mechanisms to develop anti-cachexia therapies. 

In this new study, researchers Takahiro Yamakawa, Guoxiang Zhang, Liza Bengrine Najjar, Chun Li, and Keiichi Itakura from the Beckman Research Institute of City of Hope identified the uncharacterized transcript KIAA0930 as a candidate cachexic factor based on analyses of microarray datasets and an in vitro muscle atrophy assay. 

“We here report the initial characterization of KIAA0930.”

While conditioned media from pancreatic, colorectal, gastric, and tongue cancer cells caused muscle atrophy in vitro, conditioned medium from KIAA0930 knockdown cells did not. The PANC-1 orthotopic xenograft study showed that the tibialis anterior muscle weight and cross-sectional area were increased in mice bearing KIAA0930 knockdown cells compared to control mice. Interestingly, KIAA0930 knockdown did not cause consistent changes in the secretion of inflammatory cytokines/chemokines from a variety of cancer cell lines. An initial characterization experiment showed that KIAA0930 is localized in the cytosol and not secreted from cells. 

“These data suggest that the action of KIAA0930 is independent of the expression of cytokines/chemokines and that KIAA0930 could be a novel therapeutic target for cachexia.”

 

Read the full study: DOI: https://doi.org/10.18632/oncotarget.28476 

Correspondence to: Takahiro Yamakawa

Email: tyamakawa@coh.org 

Keywords: KIAA0930, cancer cachexia, muscle atrophy, inflammatory cytokines/chemokines, protein secretion
 

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

 

Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28476

Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact: media@impactjournals.com.

 

Oncotarget Journal Office

6666 East Quaker Str., Suite 1A

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)

###


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.